Our laboratory develops biologics, such as monoclonal antibodies (mAbs), T-cell receptors (TCRs) and therapeutic enzymes. We are committed to invent enabling technologies that facilitate biologics discovery, which are important but difficult or even impossible with current methods. Bypassing the limits associated with what nature offers, we apply engineering strategies and streamline a set of synthetic / in vitro approaches including library construction, structure-aided design, mammalian cell display, functional selection, and repertoire deep sequencing. Combinations of these methods provide a powerful means for discovery and engineering highly potent biologics relevant to disease diagnosis and treatment.
